Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Aug;16(8):453.
doi: 10.1038/s41569-019-0232-z.

GLP1R agonists: primary cardiovascular prevention and oral administration

Gregory B Lim  1
Affiliations
Comment

GLP1R agonists: primary cardiovascular prevention and oral administration

Gregory B Lim. Nat Rev Cardiol. 2019 Aug.
No abstract available

PubMed Disclaimer

Comment on

  • Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
    Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189511 Clinical Trial.

References

Original articles
    1. Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet https://doi.org/10.1016/S0140-6736(19)31149-3 (2019) - DOI - PubMed
    1. Husain, M. et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1901118 (2019) - DOI - PubMed
    1. Pratley, R. et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet https://doi.org/10.1016/S0140-6736(19)31271-1 (2019) - DOI - PubMed
Further reading
    1. Nassif, M. & Kosiborod, M. Effect of glucose-lowering therapies on heart failure. Nat. Rev. Cardiol. 15, 282–291 (2018) - DOI

LinkOut - more resources